Featured

TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022

Find out more large-arrow.png

Pipeline

Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png

Presentationssmall-arrow.png

IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022

IMC Half Year Results, Feb 2022
IMC Full Year Results, Oct 2021